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ABSTRACT
Excessive telomere shortening is observed in breast cancer lesions when 
compared to adjacent non-cancerous tissues, suggesting that telomere length may 
represent a key biomarker for early cancer detection. Because tumor-derived, cell-free 
DNA (cfDNA) is often released from cancer cells and circulates in the bloodstream, 
we hypothesized that breast cancer development is associated with changes in the 
amount of telomeric cfDNA that can be detected in the plasma. To test this hypothesis, 
we devised a novel, highly sensitive and specific quantitative PCR (qPCR) assay, 
termed telomeric cfDNA qPCR, to quantify plasma telomeric cfDNA levels. Indeed, 
the internal reference primers of our design correctly reflected input cfDNA amount 
(R2 = 0.910, P = 7.82 × 10-52), implying accuracy of this assay. We found that plasma 
telomeric cfDNA levels decreased with age in healthy individuals (n = 42, R2 = 0.094, 
P = 0.048), suggesting that cfDNA is likely derived from somatic cells in which 
telomere length shortens with increasing age. Our results also showed a significant 
decrease in telomeric cfDNA level from breast cancer patients with no prior treatment 
(n = 47), compared to control individuals (n = 42) (P = 4.06 × 10-8). The sensitivity and 
specificity for the telomeric cfDNA qPCR assay was 91.49% and 76.19%, respectively. 
Furthermore, the telomeric cfDNA level distinguished even the Ductal Carcinoma 
In Situ (DCIS) group (n = 7) from the healthy group (n = 42) (P = 1.51 × 10-3). Taken 
together, decreasing plasma telomeric cfDNA levels could be an informative genetic 
biomarker for early breast cancer detection.
INTRODUCTION
Telomeres are protective DNA structures that are 
located at the end of chromosomes, and proper telomere 
maintenance is indispensable for chromosomal integrity 
and overall genomic stability. Telomere maintenance 
is normally controlled by telomerase activity as well 
as telomerase-associated factors throughout the cell 
cycle in tissue- and cell type-specific manners [1–3]. It 
is well known that telomere length in white blood cells 
is inversely correlated with age, implying that telomere 
length may serve as a biological clock to determine the 
lifespan of a cell and an organism [4]. When telomere 
maintenance is disrupted by excessive erosion of telomeric 
DNA or loss of telomere binding protein function, the 
cellular DNA damage response (DDR) becomes activated 
to repair the dysfunctional telomere [5]. Persistent 
DDR induces a permanent proliferation arrest known 
as replicative senescence, which is thought to function 
as a tumor suppressor [6–8]. However, dysregulation 
of the DDR pathway allows cells to proliferate beyond 
senescence limits. When the cells reach a stage of 
persistent telomere dysfunction (termed telomere crisis), 
these aberrant processes lead to telomere fusions causing 
genomic instability via breakage-fusion-bridge (BFB) 
cycles. As a result, the ongoing genomic instability could 
increase the occurrence of further genetic or epigenetic 
alterations that would favor neoplastic transformation. 
Therefore, telomere crisis, characterized by extensive 
telomere erosion, chromosomal fusion, and genomic 
rearrangements, is an important early event in cancer 
development [9–11].
Initially, the mean telomere length was measured 
using Southern blotting, and demonstrated that the majority 
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of invasive breast carcinomas displayed shorter telomeres 
than adjacent, benign breast tissues [12–14]. Additionally, 
results from in situ telomere length assessment (qFISH) 
indicated that modest telomere shortening occurred at 
the hyperplasia stage and a more significant shortening 
became prevalent as early as in Ductal Carcinoma In Situ 
(DCIS) [9, 15]. Telomere crisis has also been reported in 
human mammary epithelial cell in vitro culture models. 
For example, late-passage human mammary epithelial 
cells escape a stress-associated senescence-like barrier 
and acquire chromosome aberrations, including telomere 
fusions and translocations [10, 16]. Moreover, our group 
has recently demonstrated that telomere fusions are indeed 
present in early-stage breast tumors including DCIS [17]. 
Together, these findings provide strong evidence for the 
occurrence of telomere crisis-initiated genomic instability 
during early breast cancer development, probably at the 
transition from hyperplasia to DCIS [9, 15].
Mounting evidence indicates that extracellular, 
free-nucleic acids are released from the tumor cells and 
circulate in the bloodstream of cancer patients as tumor-
derived cell-free DNAs (cfDNAs), along with normal cell-
derived cfDNAs. The tumor-derived circulating cfDNA in 
plasma constitutes a potential source of genetic material 
for the identification of tumor-associated alterations, such 
as microsatellite instability, loss of heterozygosity (LOH), 
gene mutations, copy-number alternations (CNAs) and 
methylation [18–22]. Various methods have been established 
for the measurement of circulating cfDNA and the clinical 
utility of cfDNA assays has attracted significant attention 
as potential cancer biomarkers [23, 24]. Most of the current 
cfDNA assays require information on specific genetic or 
epigenetic alterations present in the original tumor lesion, 
therefore are limited to monitoring cancer progression. 
Alternatively, other cfDNA assays use a panel of frequently 
mutated genes, although the detection sensitivity still 
remains unsolved. There are thus far no established assays 
suitable for early cancer detection. Our new cfDNA assay 
presented here focuses on early breast cancer detection 
without the need for any prior information on tumor-specific 
genetic alterations. Because telomere crisis is present in 
early-stage breast tumors including DCIS we hypothesize 
that the tumor-derived cfDNA containing shorter telomeres 
is released and circulates in the bloodstream, thereby 
enabling us to quantitate telomeric cfDNA abnormality in 
plasma of women with breast cancer.
While mammography remains the most commonly 
used method for the screening and early detection of breast 
cancer, this procedure is often limited by a high medical 
cost, high false-positive rate necessitating additional testing 
and leading to patient anxiety, as well as false-negative 
results which may lead to delay of diagnosis especially 
for younger women who has dense breast tissues [25–28]. 
Biomarkers such as cancer antigen 15-3 (CA 15-3) 
and carcinoembryonic antigen (CEA) have been widely 
studied in order to monitor disease progression or response 
to therapy in patients post-diagnosed with breast cancer 
[29–31], however at this point they have unsuccessfully 
improved patient outcomes. Thus, there is a critical need 
for new diagnostic tests for breast cancer, especially 
those associated with early tumor development. Here, 
we introduce our newly developed quantitative telomeric 
cfDNA qPCR assay for measuring the levels of telomeric 
cfDNA in the plasma. Using this assay, we show a clear 
relationship between early breast cancer development 
and quantitative changes in plasma telomeric cfDNA. 
Our method potentially provides a cost-effective, time-
efficient, and convenient blood test for early detection of 
breast cancer.
RESULTS
Measurement methodology of telomeric cell-free 
DNA in plasma
First, we performed a methodological evaluation to 
determine an appropriate cell-free DNA (cfDNA) extraction 
method, including sodium iodide (NaI) method [32] and 
QIAamp DNA blood kit. We found no apparent differences 
in total cfDNA yield between healthy control group and 
cancer group isolated by NaI method (Supplementary 
Fig. S1). In contrast, QIAamp blood kit showed a slightly 
but significantly lower yield of total cfDNA in healthy group 
compared to cancer group. In addition, the cfDNA in healthy 
group extracted using the Qiagen column showed relatively 
lower yield than those using the NaI method. To eliminate 
the potential bias that a certain fraction of cfDNA might be 
lost during extraction with a silica-based membrane utilized 
in the QIAamp method (e.g., DNA fragments which are 
smaller and more difficult to extract [33]), we employed NaI 
method for isolating cfDNA from each plasma sample for 
this study. After extracting cfDNA, we carefully measured 
the cfDNA concentration by a picogreen binding assay to 
ensure that each cfDNA concentration was at least 10 pg/μL, 
because this concentration provides the minimum amount 
of input to maintain the accuracy of the qPCR assay and 
produce consistent results. No significant correlation was 
detected between the cfDNA yield and age of the patients 
(data not shown).
Plasma cfDNA is thought to be fragmented and 
not chromosomal in nature, thereby its DNA ploidy is 
likely abnormal [34]. Therefore, we expected that single 
copy genes (such as GAPDH, β-globin) are not suitable 
for qPCR-based cfDNA assays as internal references. 
In addition, it is often difficult to amplify single copy 
genes in ultra-trace amount of circulating cfDNA. To 
overcome these concerns, we designed four reference 
primers (see Materials and Methods, Supplementary 
Table S1) within the Short INterspersed Element (SINE) or 
Long INterspersed Element (LINE) nucleotide sequences, 
because approximately 13% and 17% of human genome 
consists of these non-coding repetitive SINE and LINE 
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elements, respectively [35]. After screening, we chose 
one primer set (line121F/line121R) designed within the 
LINE sequences which produced a single 121-bp amplicon 
(Fig. 1A), whereas others had either multi-amplicons or 
a gentle peak under our PCR condition; therefore, they 
were not suitable for quantifying the total amount of input 
DNA. Most importantly, threshold cycle (Ct) values of 
the new primer set (line121F/line121R) showed a linear 
correlation with cfDNA concentrations (by picogreen 
binding assay), indicating that this reference primer pair 
accurately reflects the amount of input DNA with minimal 
sample-to-sample variations (P = 7.82 × 10−52) (Fig. 1B). 
To conduct quantitative analyses of the amount of telomeric 
cfDNA, we generated DNA standard curves using plasmid 
DNAs with insert sequences of known copy numbers of 
either telomere or LINE nucleotide sequences (Fig. 1C). 
The copy number of telomere (T) was determined relative 
to the copy number of the LINE reference sequence (R) 
for each cfDNA sample, and expressed as T/R copy 
ratios. A primer pair for amplifying telomeric sequences 
was originally designed by Cawthon and produces a single 
79-bp amplicon (Fig. 1A) [36]. Throughout all experiments, 
we included an invariant endogenous control (female 
diploid genomic DNA) as well as standard plasmid DNAs 
in each PCR plate to monitor PCR efficiency and maintain 
accuracy in sample quantitation.
Plasma telomeric cfDNA amount is inversely 
associated with age in healthy women
It has been well established that average telomere 
length in peripheral blood leukocyte shortens with 
increasing age by 17 − 50 bp per year using Southern 
blotting or Cawthon’s qPCR assay [37, 38]. Therefore, 
we were interested in measuring leukocyte telomere 
length using our samples from healthy women population 
(n = 42, 27 ≤ age ≤ 73). Both single copy gene primer 
sets, albumin (ALB) and β-globin (HBG) indicated high 
reproducibility under our PCR condition (R2 = 0.914, 
P < 0.001) (Supplementary Fig. S2A). Consistent with 
published reports, we confirmed that the healthy women 
group in this study was also presented with a downward 
association between leukocyte telomere length and age 
(R2 = 0.125, P = 0.0136) (Fig. 2A). Next, to address a 
question whether age impacts telomeric cfDNA, we 
examined the distribution of telomeric cfDNA level 
using plasma samples from the same healthy women 
population. Interestingly, plasma telomeric cfDNA level 
was also inversely associated with age with variation 
(P = 0.0483), suggesting that telomeric cfDNA is likely 
derived from somatic tissues or cells in which telomere 
length is influenced by age (Fig. 2B). However, there 
was no association between plasma telomeric cfDNA 
and leukocyte telomere length in our healthy sample, 
suggesting that leukocyte DNA is not a major source of 
cfDNA production (Fig. 2C).
Level of telomeric cfDNA in plasma from breast 
cancer patients
Using the telomeric cfDNA qPCR method described 
above, we compared telomeric cfDNA levels between 
two groups, namely healthy individuals (n = 42) and a 
breast cancer group (n = 47). The baseline of demographic 
characteristics was show in Table 1. To avoid potential 
factors which may change cfDNA levels, we investigated 
Figure 1: Methodological validation of the telomeric cfDNA qPCR assay. A. Representative melting curves of single 
product amplifications using telc/telg and line121F/line121R primers. PCR was performed under 40 cycles of amplification of human 
plasma cfDNA. -Rn, the negative first-derivative of the normalized fluorescence generated by the reporter during PCR amplification. 
B. Amplification of internal reference sequence reflects input DNA amount of both plasma cfDNA and genomic DNA. Concentrations 
of experimental plasma cfDNAs (circles) as well as a serially diluted female genomic DNA samples (triangles) were determined using 
the picogreen assay. After qPCR, the amount of input DNA was plotted logarithmically against the Ct value of the reference primers. 
C. Standard curves of plasmid DNAs for calculating T/R copy ratio. Serially diluted plasmid DNA with known copy numbers of the 
telomeric or LINE sequences were plotted after the PCR. The amount of plasmid DNA standard used was optimized so that all plasma 
samples were detected within the linear range of the curves.
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plasma samples from breast cancer patients collected 
at the time of surgery, prior to any chemo-, radio- or 
hormone therapies. Overall, the telomeric cfDNA level was 
significantly lower in the breast cancer group compared 
to the healthy group. The median telomeric cfDNA as 
T/R copy ratio in the control and breast cancer group 
was 103.35 and 50.30, respectively (P = 4.06 × 10−8) 
(Fig. 3A). We also determined the sensitivity and specificity 
of this new assay by construction of Receiver Operating 
Characteristic (ROC) curves (Fig. 3B). Telomeric cfDNA 
showed the diagnostic accuracy with an area under the 
ROC curve (AUC) of 0.8652 (95% Confidence Interval: 
0.7867–0.9438, P < 0.0001), which is a measure of how 
well a parameter can distinguish between two groups. At the 
cutoff value of 91.40 (T/R copy ratio) for telomeric cfDNA, 
the optimal sensitivity and specificity were 91.49% and 
75.19% respectively. Moreover, the positive and negative 
predictive values (PPV and NPV) were 82.35% and 86.84%, 
which represents the percentage of patients with a positive 
and negative test of those individuals who actually have 
the disease and no disease, respectively. Since we found 
that telomeric cfDNA decreased with age in the healthy 
population (Fig. 2A), we divided the results into subsets by 
age (Fig. 3C). Overall, unlike the control healthy group, there 
was no correlation between telomeric cfDNA level and age 
in the breast cancer group. This observation is in agreement 
with previous findings that telomere length in breast tumor 
tissues was not associated with age [12], suggesting that a 
substantial fraction of cfDNA in the plasma of breast cancer 
patients could be of tumor origin. In the women younger 
than 41 and older than 51, the T/R cutoff value of 91.40 (T/R 
copy ratio) readily distinguished healthy from breast cancer 
patients. However, in the group aged between 41 and 50, 
telomeric cfDNA level was not able to distinguish breast 
cancer patient from healthy controls (P = 0.053), although 
we detected a tendency of lower T/R copy ratio in the breast 
Table 1: Characteristics of study groups
Healthy individuals Breast cancer patients P-value
Total number 42 47 —
Age, years 44.8 ± 9.5 51.0 ± 11.5 0.007
≤40 n = 14 n = 10 —
41–50 n = 13 n = 14 —
51≤ n = 15 n = 23 —
Sex Female Female —
Ethnicity Caucasian Caucasian —
Height, cm 167.3 ± 5.6 164.4 ± 8.8 0.07 (N.S.*)
Weight, kg 62.8 ± 6.0 77.3 ± 18.0 <5 × 10−6
BMI 22.4 ± 1.9 28.5 ± 6.0 <5 × 10−7
Values expressed with a plus/minus sign are means ± S.D.
*N.S., Not significant.
Figure 2: Chronological age has impact on both leukocyte telomere length and plasma telomeric cfDNA level in the 
control healthy group. A–B. Relationships between age and leukocyte telomere length (A) or their paired plasma telomeric cfDNA 
levels (B) Each data from healthy control subjects (n = 42) was plotted with age at time of donation. P-value of the linear regression 
was calculated by GraphPad Prism version 5.00. C. No strong association between plasma telomeric cfDNA levels (T/R copy ratio) and 
lymphocyte telomere length (T/S ratio). All plasma T/R results were plotted against their paired lymphocyte telomere length.
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cancer group (Fig. 3C). This statistical insignificance could 
be due to the small sample size. Since this slight difference 
mainly resulted from high variation of telomeric cfDNA 
level in healthy individuals, we speculate that hormonal 
changes or imbalance at the premenopausal stage may have 
contributed to this variation.
Several reports suggest that cfDNA levels are 
associated with the degree of tumor differentiation, size, 
or disease stage [39–41]. Thus, we categorized the breast 
cancer population according to the size of the primary 
tumor ranged from Tis to T3. The clinical characteristics of 
cancer patients were shown in Supplementary Table S2. 
The Tis stage defines carcinoma in situ and all 7 cases from 
the Tis stage were DCIS in this study. Notably, our results 
showed that telomeric cfDNA levels clearly discriminated 
the DCIS group from the control group (58.16 vs. 103.35, 
P = 1.51 × 10−3) (Fig. 3D). This finding provides evidence 
that our newly developed telomeric cfDNA qPCR assay 
has great promise to capture women at the pre-malignant 
stage. However, we were not able to determine whether 
an association exists between telomeric cfDNA levels 
and tumor size, although there is a tendency of lower T/R 
copy ratio with increasing tumor size. This is likely due to 
current limited sample size. The breast cancer population 
was also categorized according to their lymph node 
involvement (Supplementary Fig. S3A). Again we did 
not detect an association between telomeric cfDNA level 
and lymph node invasiveness, pointing out that our assay 
detects aberrant telomeric cfDNA reduction even at the N
0
 
stage before any lymph node metastasis. Moreover, it is 
unlikely that adiposity is associated with telomeric cfDNA 
levels because the telomeric cfDNA amount in breast 
Figure 3: Telomeric cfDNA levels in breast cancer patients were significantly lower than those from controls. A. Box 
plot for plasma T/R copy ratios measured in the control and breast cancer groups. B. ROC curves for the accuracy of T/R copy ratios in 
distinguishing breast cancer patients from healthy individuals. Both non-parametric (blue) and fitted parametric curves (red) were shown. 
C. Breast cancer T/R copy ratio abnormality in different age groups. T/R copy ratios were compared between the control group and the 
breast cancer group in three age categories (≤ 40, 41 – 50, and 51  ≤). D. T/R copy ratio comparison in control and breast cancer cases 
categorized by tumor size. Median T/R copy ratio in each category was shown.
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cancer patients is consistently low regardless of Body 
Mass Index (BMI) (Supplementary Fig. S3B).
Level of plasma centromeric cfDNA in both 
healthy and breast cancer women
To determine whether tumor-driven cfDNA was 
abnormal only in amounts of telomeric sequences or 
amounts of other repetitive sequences, we investigated 
centromeric cfDNA levels using the same plasma 
samples described above. Indeed, there have been several 
observations of centromere instability, such as centromeric 
fissions found in human cancer [42, 43]. Pan-centromeric 
primers were designed within alpha-satellite DNA and can 
amplify as a single product from at least 15 chromosomes 
in silico (Supplementary Fig. S4A). Overall, the median 
centromeric cfDNA levels in the control group was 
2.52 × 10−2 as C/R copy ratio, and the median centromeric 
cfDNA level in the breast cancer group was 2.31 × 10−2 
as C/R copy ratio (Fig. 4A). Although this difference 
was statistically significant (P = 0.017), an AUC of 
the ROC curve indicated that the diagnostic value of 
centromeric cfDNA was not very high (AUC = 0.6484, 
95% Confidence Interval: 0.5328 – 0.7640, P = 0.0161) 
(Fig. 4B). At the cutoff value of 2.42 × 10−2 (C/R copy 
ratio) for centromeric cfDNA, the optimal sensitivity 
and specificity were 65.96% and 66.67% respectively. 
Moreover, in contrast to telomeric cfDNA levels, 
centromeric cfDNA levels in the healthy control group 
were not associated with age (Fig. 4C). When the breast 
cancer cases were subcategorized by tumor size (Tis to T3), 
our results showed that the difference in centromeric 
cfDNA levels between the DCIS group and the control 
group was statistically significant (P = 0.0206). However, 
the actual difference in their C/R copy ratios was merely 
10% (2.29 × 10−2 vs. 2.52 × 10−2) (Fig. 4D). Thus, these 
Figure 4: Centromeric cfDNA levels were not highly valuable as a marker for breast cancer detection. A. Box plot 
for plasma C/R copy ratios measured in the control and breast cancer groups. B. ROC curves for the accuracy of C/R copy ratios in 
distinguishing breast cancer patients from healthy individuals. Both non-parametric (blue) and fitted parametric curves (red) were shown. 
C. No strong association between centromeric cfDNA levels (C/R copy ratio) and age at time of donation. Open circles, healthy control 
group; Filled circles, breast cancer cases. D. C/R copy ratio comparison in control and breast cancer cases categorized by tumor size. 
Median C/R copy ratio in each category was shown.
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findings suggest that centromeric cfDNA amounts are 
unlikely to be a desirable marker for cancer detection, 
although we do not rule out the biological significance of 
centromeric cfDNA levels in cancer development.
DISCUSSION
Our present study focused on establishing a new 
strategy to assess circulating cfDNA for detecting early 
breast cancer. Since plasma contains ultra-trace amount 
of circulating cfDNA, roughly around 100 ng per ml of 
plasma in cancer patients among different laboratories 
[44, 45], various cfDNA methods often require a certain 
amplification step to improve enrichment of cfDNA prior 
to analyzing tumor-specific alterations in cfDNA [46, 47]. 
The new quantitative real-time PCR method that we 
applied in this present study has no enrichment step and 
only requires 50 to 150 pg cfDNA per reaction. Our new 
method quantitates changes in the amount of repetitive 
telomeric DNA sequences that are abundant and spread 
throughout the genome, rather than a single copy sequence 
per genome.
Circulating cfDNA can be isolated from human 
plasma, serum and other body fluids, and represents a 
novel biomarker of interest for cancer diagnosis and 
monitoring. Increasing studies provide evidence that 
circulating cfDNA serve as liquid biopsy for monitoring 
the changes occurring in a patient’s cancer in real-time 
[41, 48]. Initial studies reported that elevated levels of 
total cfDNA were identified in breast cancer patients 
compared with healthy controls due to the presence 
of tumor-driven circulating cfDNA. However, these 
findings are still inconclusive because large individual 
variations in cfDNA quantity have been observed among 
different studies [41, 49, 50]. In this study, we observed 
no elevated levels of total cfDNA from the cancer group 
compared to those from the healthy group using the NaI-
based extraction method (Supplementary Fig. S1). While 
the exact mechanism is currently unknown, this could 
be potentially explained by the following factors: 1) the 
release of tumor cfDNA might suppress normal somatic 
cells to release cfDNA, and 2) the systematic capacity of 
cfDNA clearance/degradation might be higher in breast 
cancer patients than healthy subjects, thus leading to 
similar levels of total cfDNA. The integrity of cfDNA has 
also been investigated by comparing the ratio of apoptotic 
fragments to non-apoptotic cfDNA fragments [51, 52]. 
Those studies suggest that apoptotic fragmentations 
are less abundant in plasma/serum cfDNA from cancer 
patients compared to that from normal controls. By using 
qPCR, digital PCR, or sequencing technologies, recent 
studies reported that PIK3CA and/or TP53 mutations 
status could be obtained from cfDNA in advanced breast 
cancer patients before, during and after targeted therapy 
[20, 48]. However, these studies focused on patients 
with high tumor burden, and it remains to be evaluated 
whether similar sensitivity can be achieved in patients at 
the earlier stages of breast cancer. Moreover, monitoring 
these two mutations are not sufficient to capture all types 
of breast cancer; therefore, a panel of cancer-specific gene 
mutations would have to be assessed.
To the best of our knowledge, our study is 
the first to report that pre-malignant DCIS patients 
can be discriminated from healthy individuals using 
plasma circulating cfDNA. This finding contributes to 
accumulating evidence that telomere-based crisis in 
which telomere erosion, genomic instability, and massive 
cell death are concomitantly increased in tumor lesions, 
and can be identified during the transition from ductal 
hyperplasia to DCIS [9, 15]. Although the biology and 
physiology of cfDNA circulation is not well understood, 
our data may support the hypothesis that the lower 
telomeric cfDNA levels in the breast cancer groups 
(even at the DCIS stage) result from the presence of 
tumor-derived cfDNA with shortened telomeres in the 
bloodstream. Further, these findings may suggest that 
tumor cells with shortened telomeres might be prone to 
cell death and preferentially provide cfDNA. Notably, 
we found that telomeric cfDNA levels in cases with 
advanced breast tumors (stages II – III) was significantly 
lower than those in cases at earlier stages of breast cancer 
(stages 0 – I) (P = 7.12 × 10−3, Supplementary Fig. S5). 
As telomere length at breast tumor lesions shortens with 
the development of cancer, this result may strengthen 
our hypothesis that the decreased telomeric cfDNA 
levels results from the shortening of telomere length at 
breast cancer tissues. It is thought that plasma cfDNA 
from cancer patients is a mixture of tumor-derived and 
non-tumor-derived DNA. A few studies have estimated a 
small to modest fraction of tumor-derived cfDNA in the 
total plasma cfDNA of cancer patients (range 1 – 50%, 
median ~ 4%) [48, 53]. Nonetheless, in this present 
study we demonstrated that plasma telomeric cfDNA 
levels were significantly lower in breast cancer patients 
compared to healthy controls while the exact mechanism 
is not currently understood. Since all previous studies 
estimating the tumor-derived fraction used only one or two 
tumor-specific alterations (e.g. specific chromosome arm 
loss/gain, allelic mutations) to represent the pool of total 
tumor cfDNA, it is possible that the tumor-derived cfDNA 
fractions were underestimated and the actual tumor-
derived cfDNA may be more abundant than currently 
thought. Since the main focus of this study is on early 
detection of cancer rather than cfDNA biology, future 
characterization of plasma cfDNA (e.g., size distribution, 
fraction ratio) in cancer patients would lead to better 
understanding of the cfDNA biology.
In addition, it is speculated that telomeric cfDNA 
levels might be influenced by interweaving factors such 
as metabolic regulation, hormone balance, and nuclease 
activity levels in the bloodstream [54–56]. In fact, our 
results show that telomeric cfDNA levels in the healthy 
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control group were quite variable (range: 34.42 – 274.51, 
mean: 115.57, as T/R copy ratio), even though we carefully 
selected the control group by eliminating any potential 
confounding factors (see Materials and Methods). Nine out 
of total 42 controls were detected as false positive, and the 
majority of these were individuals aged between 41 and 50 
(6 of 9 cases). While not definitive, we suspect that a phase 
of menstrual cycle and/or menstruation status might alter 
normal telomeric cfDNA levels. In the breast cancer group, 
our telomeric cfDNA data detected a statistical outlier (as 
false negative) in two cases which are ER+/PR+/HER2− and 
normal BMI from Stage IA without any family history. 
One possible explanation of these false negative results 
could be involvement of ALT (alternative lengthening 
mechanisms of telomeres) pathway in which tumors 
often have heterogeneous telomere length with relatively 
longer telomeres [57]. Indeed, the ALT phenotype has been 
reported in ~5% of breast epithelial malignancies [58].
Currently telomere length measurement has been 
utilizing peripheral leukocyte DNA in large cohorts, 
especially in the scope of estimating cancer risk and 
mortality. However, results from these studies remain 
conflicting rather than conclusive. For instance, several 
case-control studies showed that short leukocyte telomere 
length was associated with increased risk of breast cancer 
[59, 60], while others indicated contradictory [61, 62] 
or insignificant associations [63, 64]. The inconsistent 
conclusions of these epidemiologic studies are perhaps, 
in part, explained by the lack of standardized method and 
analysis between laboratories. Additionally, leukocyte 
telomere length might not be directly associated with 
breast epithelial carcinogenesis, because leukocyte 
telomere length is also influenced by other factors such as 
smoking, adiposity, exercise, oxidative stress, ultraviolet 
irradiation, and social and economic status [65, 66]. 
Therefore, further investigation is critical to understanding 
the usefulness of leukocyte telomere length as a surrogate 
marker of cancer risk and mortality. It would also be 
interesting to further investigate whether our telomere 
cfDNA qPCR assay can be applied for early detection 
of not only breast cancer, but other types of cancer as 
well. If the telomere cfDNA aberration is a universal 
phenotype in various types of carcinogenesis, this new 
assay has potential as cancer risk assessment or screening 
test in other cancer types. It is also important to examine 
non-cancerous patients with benign disease to determine 
whether telomeric cfDNA abnormality is correlated 
specifically with breast carcinogenesis.
In summary, this study highlights the quantitative 
abnormality of plasma telomeric cfDNA observed in 
patients with pre-malignant DCIS. The exciting results 
presented a call for future studies testing the assay’s 
potential for clinical utility. Our approach of measuring 
the amount of telomeric cfDNA in plasma could serve as 
a liquid biopsy, which would be useful for improving early 




The Indiana University Institutional Review Board 
approved the use of human plasma samples. About 1 mL 
of frozen plasma samples of breast cancer patients (n = 47, 
32 ≤ age ≤ 73) and control healthy women (n = 42, 
27 ≤ age ≤ 73) were obtained through the IU Simon 
Cancer Center Tissue Procurement and Distribution 
Core and the Susan G. Komen Tissue bank, respectively. 
All samples were collected in accordance with standard 
operating procedures described in the facilities’ website 
and with donor’s written informed consent. All healthy 
samples were obtained from Caucasian women with 
no family history, no current tobacco nor hormone use, 
average BMI, and lifetime Gail score < 20%. All breast 
cancer patient samples were from women who underwent 
surgery without combination therapies to eliminate 
potential confounding factors. Blood from cancer patients 
was obtained at the time of surgery. The demographical 
and clinical information was shown in Table 1 and 
Supplementary Table S2.
Plasma cell-free DNA extraction
Frozen plasma samples were thawed on ice 
prior to cfDNA isolation and centrifuged for 3 min 
at ≥ 11,000 × g in order to remove residual cells, cell 
debris, and particulate matter. 150 μL of aliquoted 
supernatant was used for each cfDNA extraction using a 
Sodium Iodide (NaI)-based method [32]. Briefly, 150 μL 
plasma was mixed with equal amount of a 2 × Enzyme 
reaction solution and proteinase K (Roche) was added 
to a final concentration of 1 mg/ml. The mixture was 
incubated at 56°C for 30 minutes, and then combined 
with 1.5 volume of 7.6 M sodium iodide solution, 1 μL of 
glycogen (20 mg/ml stock), and 1 volume of isopropanol. 
After vortexing, the samples were incubated for 30 min 
at room temperature with agitation. Precipitated cfDNA 
was centrifuged and washed with 40% w/v isopropanol 
and then 70% ethanol. Finally, DNA pellet was air-dried 
and dissolved in 50 μL of TE buffer. For comparison 
of cfDNA extraction methods, plasma samples were 
also extracted using the QIAamp DNA Blood Mini kit 
(Qiagen) according to the manufacturer’s instructions with 
a starting plasma volume of 300 μL and elution of 50 μL 
in buffer AE.
Measurement of total plasma DNA concentration
Plasma cfDNA concentrations after extraction were 
measured using Quant-iT TM PicoGreen dsDNA Assay 
Kit (Life Technologies) according to the manufacturer’s 
instruction. A female genomic DNA (cat# G152A, 
Promega) was diluted to 50 pg/μL and used to generate 
the low-range standard curve in each plate. Fluorescence 
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intensity was measured with a Synergy 2 Multi-Mode 
Reader at emission wavelength of 520 nm and excitation 
wavelength of 480 nm.
Quantitative PCR-based cfDNA assays
Real-time quantitative PCR (qPCR) were 
performed on ABI 7500 Real-Time PCR system (Applied 
Biosystems). The final volume of PCR reaction was 15 μL 
using 1× SYBR Select (Applied Biosystems) including 
primers and cfDNA as template. cfDNA was added in each 
primer set using the following ratio; telomere: centromere: 
LINE = 5: 1: 1. Therefore, if 150 pg cfDNA was used 
for telomere primers, 30 pg was used for both centromere 
and LINE primers. telg and telc primers were used for 
amplification of the telomere signal (T), which generate 
a 79 bp product (final concentrations 900 nM each) [36]. 
The primer sequences were as follows: 5′-ACA CTA AGG 
TTT GGG TTT GGG TTT GGG TTT GGG TTA GTG 
T-3′ for telg, and 5′-TGT TAG GTA TCC CTA TCC CTA 
TCC CTA TCC CTA TCC CTA ACA-3′ for telc. The other 
primer sequences were used for the pan-centromere signal, 
cen96F, 5′-TTC ATC TCA CAG AGT TGA ACC TTT 
CCT TTG-3′, and cen96R, 5′-GGC CTC AAA GTG TAC 
CAA ATA TCC ACT TG-3′ (final concentrations 400 nM 
each). For the reference sequence (R), line121F, 5′-GGA 
TTA AGA AAA TGT GGC ACA TAT ACA CCA TGG- 3′ 
and line121R, 5′-GAT AGT TTA CTG AGA ATG ATG 
GTT TCC AAT TTC AT-3′ (final concentrations 250 nM 
each). The thermal cycling profile is Stage 1 for 10 min at 
95°C; Stage 2 for 2 cycles of 15 s at 94°C, 15 s at 49°C; 
and Stage 3 for 40 cycles of 10 s at 94°C, 10 s at 62°C, 
10 s at 74°C.
Analysis of telomeric and centromeric cfDNA 
qPCR assay
qPCR results were analyzed by generating plasmid 
DNA standard curves. Therefore, the relative quantitation 
is based on T/R or C/R copy ratios of each copy number 
from the standard curves. Five concentrations of a 
plasmid DNA sample were prepared with known copies 
of the telomere, centromere, and LINE (Long INterspersed 
Element) nucleotide sequences by serial dilution 
(Fig. 1C and Supplementary Fig. S4B). To monitor and 
compensate for inter-plate variations in PCR efficiency, 
each plate included standard plasmid DNAs as well as 
female genomic DNA (Promega). All experimental DNA 
samples were repeated at least three times in triplicate. 
All samples have a standard deviation of less than 0.5 
for the threshold cycle (Ct) values. Ct values and melting 
curve analysis were generated by the 7500 software v2.3. 
The coefficients of variation (CVs) for the Ct values of 
telomere, centromere, and LINE primers were 1.5%, 
2.2%, and 1.0%, respectively. Melting curve analysis 
was performed on every run to verify specificity and 
identity of the PCR products. The telomere amount (T) 
or centromere amount (C) were presented as T/R or C/R 
copy ratios where T/R = (telomere copy number) / (Line 
copy number), and C/R = (centromere copy number)  / 
(Line copy number). The final quantity reported result is 
the average of three independent experiments.
Control plasmid DNA preparation for cfDNA 
assays
The plasmid DNAs containing known sequences 
of the pan-centromeric or LINE DNA was constructed by 
ligating the PCR product of the pan-centromere or LINE 
primers to the pGEM-T easy vector (Promega) or the 
PCR 2.1 TOPO vector (Life Technologies), respectively. 
A plasmid containing [TTAGGG]
11
 sequences was 
obtained from Dr. David Gilley (Indiana University). All 
plasmid DNAs were diluted in PCR grade water. Copy 
number calculation was performed as described previously 
[67]. Plasmids were linearized using proper enzymes 
before use.
Telomere length qPCR
Paired leukocyte DNAs along with plasma from 
healthy women were obtained as a lyophilized power after 
the Komen Tissue Bank was extracted from whole blood 
samples using the Flex Star automated system with the 
AGFStar Fresh WB Extraction Kit (Autogen, cat# AGKT-
WB-640). Telomere length qPCR was performed ABI 
7500 Real-Time PCR system and analyzed as described 
previously [36, 68]. The telomere primers (telg and telc, 
final concentrations 900 nM) were used for telomere 
signal (T). As internal reference (single copy gene 
signal = ‘S’), two primer sets within albumin and β-globin 
genes were used (final concentrations 500 nM each). 
The β-globin (HBG) primers were described previously 
[69]. The albumin (ALB) primer sequences were 5′-TTG 
AAT TTC TGC TCT CCT GCC TGT T-3′ and 5′-GTC 
ACT TAC TGG CGT TTT CTC ATG C-3′. To calculate 
the T/S ratios, each DNA standard curve was generated 
using a pooled female genomic DNA (Promega, G152A) 
(Supplementary Fig. S2B).
Statistical analysis
The differences in the distribution of T/R or C/R 
ratios between breast cancer cases and controls, as well as 
the final cfDNA yield between the NaI and Qiagen method 
were compared using the Student’s t-test, and Pearson’s 
correlation analysis was performed for  correlation 
evaluations. A P value of less than 0.05 (two-tailed) was 
considered significant. Receiver operating characteristic 
curves (ROCs) were used to evaluate the diagnostic 
performance of T/R and C/R copy ratios. The non-
parametric (empirical) ROC curve, as well as the area 
under the curve (AUC), standard error, 95% confidence 
interval (CI), and P value were generated using the 
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GraphPad Prism version 5.00 (GraphPad Software, San 
Diego, California USA). The fitted, parametric ROC curve 
and statistical analysis were generated and performed by 
the Web-based Calculator for ROC curves (Java translated 
by John Eng, Department of Radiology and Radiological 
Science, Johns Hopkins University School of Medicine) 
based on the original Fortran program LABROC4 by 
Charles Metz & colleagues (Department of Radiology, 
University of Chicago).
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